Compare ATMU & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATMU | ERAS |
|---|---|---|
| Founded | 1958 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 5.5B |
| IPO Year | 2023 | 2021 |
| Metric | ATMU | ERAS |
|---|---|---|
| Price | $48.49 | $11.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | ★ $58.25 | $14.25 |
| AVG Volume (30 Days) | 1.1M | ★ 8.2M |
| Earning Date | 05-01-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.36% | N/A |
| EPS Growth | 12.61 | ★ 36.23 |
| EPS | ★ 0.59 | N/A |
| Revenue | ★ $1,764,300,000.00 | N/A |
| Revenue This Year | $15.00 | N/A |
| Revenue Next Year | $5.13 | N/A |
| P/E Ratio | $82.96 | ★ N/A |
| Revenue Growth | ★ 5.67 | N/A |
| 52 Week Low | $34.58 | $1.06 |
| 52 Week High | $66.50 | $24.28 |
| Indicator | ATMU | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 32.56 | 45.04 |
| Support Level | $43.53 | $9.80 |
| Resistance Level | $51.84 | $16.14 |
| Average True Range (ATR) | 1.92 | 0.70 |
| MACD | -0.70 | 0.18 |
| Stochastic Oscillator | 13.83 | 92.17 |
Atmus Filtration Technologies Inc manufactures filtration products for on-highway commercial vehicles and off-highway agriculture, construction, mining, and power generation vehicles and equipment. The company designs and manufactures Developed filtration products, principally under the Fleetguard brand, that enable lower emissions and provide asset protection. It designs, manufactures, and sells filters, coolants, and chemical products. The company offers products including air filtration, coolants and chemicals, crankcase ventilation, fuel filtration, fuel cells, lube filtration, and others.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.